Antegren BLA Submission For Multiple Sclerosis Could See Approval By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec and Elan are requesting priority review for the MS submission. Companies are also seeking accelerated approval; BLA is based on one-year data from ongoing AFFIRM and SENTINEL trials.
You may also be interested in...
Biogen Idec/Elan's Tysabri Priced At Premium To Serono/Pfizer's Rebif
With a wholesale acquisition cost of $1,808, Tysabri will sell for at least a 20% premium to Rebif. Pricing for the MS therapy reflects the expectation of future indications in Crohn's and rheumatoid arthritis.
Biogen Idec/Elan's Tysabri Priced At Premium To Serono/Pfizer's Rebif
With a wholesale acquisition cost of $1,808, Tysabri will sell for at least a 20% premium to Rebif. Pricing for the MS therapy reflects the expectation of future indications in Crohn's and rheumatoid arthritis.
Tysabri's Next Steps Include Rheumatoid Arthritis, Crohn's Indications
Elan/Biogen Idec may price the recently approved Tysabri at a premium to other multiple sclerosis therapies in anticipation of the additional indications. The price announcement could come within a few days.